Global Pharma Chooses Eastern Europe For Clinical Research

The U.S. Food and Drug Administration (FDA) published its Novel Drug Approvals Report for 2021. 33 out of 50 drugs underwent clinical trials in Eastern Europe. With the total population pool of 300 million, countries like Poland, Latvia, Hungary, Romania, Czech Republic, Ukraine, Bulgaria, Russia, Georgia, Belarus and Kazakhstan demonstrate record-breaking recruitment rates with a significant number of treatment naïve study subjects.

Read the annual Industry Pages report, prepared by OCT Clinical, a European CRO, to find out why global pharma considers the region as the best destination for their clinical research activities.